PO.CL01.20 · 临床研究
通过应对分析前因素的影响,实现游离DNA采集管中的多组学分析
Enabling multiomic analysis in cell-free DNA tubes by addressing the impact of pre-analytical factors
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:游离DNA(cfDNA)采集管因其在保证cfDNA稳定性的同时允许采血后延迟处理,已被广泛用于基因组液体活检。然而,对于其他分析物(尤其是血浆蛋白)在延迟处理期间承受分析前应激时能否在cfDNA采集管中保持稳定,目前仍知之甚少。本研究探讨了运输过程中的时间和温度变化对采集于Streck cfDNA采集管中样本蛋白谱的影响,以及一种用于减轻该影响的计算方法。
方法:我们采集了10名健康供者的血液至Streck cfDNA采集管中。在不同时间点以及暴露于不同温度条件后分离血浆,以模拟运输应激。使用免疫蛋白质组学分析平台共检测了2,903种蛋白,以评估蛋白丰度的变化。我们还评估了一种计算回归方法,以校正分析前因素对基于磁珠的多重免疫测定所检测蛋白水平的影响,并确定生物标志物候选物在临床队列中的效应量变化(癌症 n=105 对比 对照 n=538)。
结果:以20%的丰度变化作为阈值,我们观察到超过半数的蛋白(1,574种)在长时间和温度暴露下保持稳定。虽然351种蛋白表现出负向偏倚,但大多数扰动(978种)为浓度升高,其中来自血细胞的蛋白占比过高。某些蛋白,如巨噬细胞移动抑制因子(MIF),与血浆血红蛋白(Hb)水平高度相关,提示存在红细胞(RBC)溶解效应。其他蛋白,如表皮生长因子(EGF),则与血浆钾(K)水平更相关,提示涉及其他血细胞类型的更广泛溶解效应。利用独立的临床队列,我们证实MIF和EGF水平分别与Hb和K高度相关。回归结果显示,经Hb回归校正后,病例组与对照组之间MIF的Hedges' g效应量从0.184增至0.468,而经K回归校正后EGF的Hedges' g从0.318增至0.467,证明了该计算方法在揭示潜在蛋白生物标志物方面的能力。
结论:分析前变量显著影响cfDNA采集管中的血浆蛋白质组谱,尤其是与血细胞相关的蛋白。cfDNA采集管中蛋白丰度对分析前应激的响应变化可能干扰分析并导致假阳性发现。我们的结果表明,利用K和Hb等分析前标志物可通过计算方法减轻这种变异性。实施稳健的样本质量控制和计算校正策略,对于确保来自cfDNA采集管样本的血浆蛋白质组检测的可靠性至关重要。
查看英文原文 English abstract
Background : Cell-free DNA (cfDNA) tubes are widely adopted for genomic liquid biopsies because they allow delayed processing after blood collection while ensuring cfDNA stability. However, it remains poorly understood whether other analytes, especially plasma proteins, are stable in cfDNA tubes when subjected to preanalytical stresses during delayed processing. This study investigates the effect of time and temperature variations during transit on protein profiles in samples collected in Streck cfDNA tubes, and a computational method to mitigate the impact.
Methods: We collected blood from 10 healthy donors into Streck cfDNA tubes. Plasma was separated at varying time points and after exposure to different temperature conditions to simulate shipping stress. A total of 2,903 proteins were measured using an immuno-proteomic profiling platform to assess changes in protein abundance. We also assessed a computational regression approach to correct for preanalytical impact on protein levels measured by a bead-based multiplex immunoassay and determine the effect size change of biomarker candidates in a clinical cohort (cancer n=105 vs. control n=538).
Results: Using a 20% abundance change cutoff, we observed that over half of the proteins (1,574) remained stable over prolonged time and temperature exposure. While 351 proteins showed negative bias, the majority of perturbations (978) were concentration increases, with proteins from blood cells overrepresented. Some proteins, such as Macrophage Migration Inhibitory Factor (MIF), were highly correlated with plasma hemoglobin (Hb) level, indicating a red blood cell (RBC) lysis effect. Other proteins, such as Epidermal Growth Factor (EGF), were more correlated with plasma potassium (K) level, suggesting broader lysis effects involving other blood cell types. Using the independent clinical cohort, we confirmed that MIF and EGF levels were highly correlated with Hb and K, respectively. The regression results showed that the Hedges' g effect size for MIF between case and control groups increased from 0.184 to 0.468 after Hb-regression, and the EGF Hedges' g increased from 0.318 to 0.467 after K-regression, demonstrating the power of this computational method to unmask potential protein biomarkers.
Conclusions: Preanalytical variables significantly impact plasma proteomic profiles in cfDNA tubes, especially for proteins that are associated with blood cells. The protein abundance changes in response to preanalytical stresses in cfDNA tubes can confound analyses and lead to false findings. Our results demonstrate that leveraging preanalytical markers like K and Hb allows for computational mitigation of this variability. Implementing robust sample quality control and computational correction strategies is essential to ensure the reliability of plasma proteomic measurements from samples collected in cfDNA tubes.
利益披露 Disclosure
S. Zhao,
Freenome Employment.
T. Hsu,
Freenome Employment.
F. Apolinario,
Freenome Employment.
A. Martinez-Horta,
Freenome Employment.
Y. Zhong,
Freenome Employment.
A. Rao,
Freenome Employment.
J. Lin,
Freenome g., Board of Directors, non-salaried role).
R. Bourgon,
Freenome Employment.
T. Moreno,
Freenome Employment.
O. Shapira,
Freenome Employment.
K. Li,
Freenome Employment.